Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.41 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22084395 | 1.00 | ADORA2A (0.41) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22084397 | 0.89 | PDE10A (0.40) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22084423 | 0.88 | LPL (0.39) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22085119 | 0.86 | PDE10A (0.42) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22084394 | 0.86 | ADORA2A (0.38) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22084387 | 0.84 | PDE10A (0.48) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22084396 | 0.84 | ADORA2A (0.41) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22084424 | 0.83 | PDE10A (0.38) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22085121 | 0.82 | PDE10A (0.46) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22084385 | 0.82 | PDE10A (0.46) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220041627-A1 | PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041627-A1 | PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF | ENPP2, PAICS, TPMT | ADORA2A 415/4885PI4KA 1584/4885PI4K2B 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.